Results 201 to 210 of about 389,222 (268)

Reduced Circulating HIF-1α, HIF-2α, HIF-3α, and VHL Levels in Patients With Pulmonary Arterial Hypertension. [PDF]

Pulm Circ
Kan H, Alsancak Y, Uyaner Kan M, Göktaş E, Çelik M, Gürbüz AS, Düzenli MA.   +6 more
europepmc   +1 more source

Multivariate linear regression to predict association of non‐invasive arterial stiffness with cardiovascular events

ESC Heart Failure, Volume 12, Issue 2, Page 1141-1150, April 2025.
Abstract Background Arterial stiffness is a crucial factor in determining an increase in systolic blood pressure and pulse pressure and can also predict the development of cardiovascular disease (CVD). The purpose of this study was to examine the relationship between arterial stiffness and future CVD.
Susan Darroudi, Mostafa Eslamiyeh, Amin Mansoori, Eisa Nazar, Maryam Alinezhad‐Namaghi, Reza Rezvani, Majid Ghayour‐Mobarhan, Habibollah Esmaily, Mohsen Moohebati, Gordon A. Ferns, Mark Ghamsary   +10 more
wiley   +1 more source

Molecular and pathophysiological intersections between arterial hypertension, pulmonary inflammation and diabetes mellitus. [PDF]

Front Pharmacol
da Silva HJN, Lima-Filho ACM, Pereira EM, Sousa IJO, Cunha FVM, Lucarini M, Durazzo A, Sousa LDR, Arcanjo DDR.   +8 more
europepmc   +1 more source

The outcomes of electronic personal health records in patients with heart failure or coronary artery disease

ESC Heart Failure, Volume 12, Issue 2, Page 1464-1468, April 2025.
Abstract Background There are limited data on the efficacy of smartphone‐based personal health records (PHRs) in patients with cardiovascular disease. This study aimed to examine the processes, outcomes and challenges associated with the implementation of integrated PHRs in patients with heart failure (HF) or coronary artery disease (CAD). Methods This
Kotaro Nochioka, Satoshi Yasuda, Takashi Shiroto, Saori Yamamoto, Haruka Sato, Yuhi Hasebe, Shigeo Godo, Makoto Nakano, Tomohiko Shindo, Kensuke Nishimiya, Kiyotaka Hao, Jun Takahashi, Keisuke Ido, Yoichi Kakuta, Hiroaki Shimizu, Hiroaki Shimokawa, Masaharu Nakayama   +16 more
wiley   +1 more source

Targeting the Hippo pathway in pulmonary arterial hypertension: emerging pharmacological strategies. [PDF]

J Hypertens
Zheng D, Guo Y.
europepmc   +1 more source

Transitioning From Oral to Intravenous Treprostinil in Pulmonary Arterial Hypertension: A Case Report. [PDF]

Clin Case Rep
Cummings AM, Konkol SB, Mihalek AD, Roth ME.   +3 more
europepmc   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Association Involving Systemic Arterial Hypertension, Tinnitus, and Hearing Loss: A STROBE-Based Review. [PDF]

Int Arch Otorhinolaryngol
Tavares LA, Peres R, Redig LB, Guilhon ACR, Couto LGD, Andriolo BN.   +5 more
europepmc   +1 more source

Risk Trajectory and Right Ventricular Adaptation in Selexipag-Based Triple Therapy for Pulmonary Arterial Hypertension. [PDF]

Anatol J Cardiol
Mahida K, Jagtap SR.
europepmc   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source